CWBHF | Ticker Profile - Titan Protect

CWBHF

Charlotte's Web Holdings, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic · OQX

$0.43

Data: 2026-05-13

✗ ETHICAL FAIL

WEAK MOAT

HIGH

Data Confidence: 100.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$77M

Total market value of the company

Trailing P/E

0.00

Forward P/E

48.01

Based on estimated future earnings — lower means cheaper

Rev Growth

+5.2%

Year-over-year revenue change

Profit Margin

-59.6%

How much profit the company keeps from each dollar of revenue

ROE

-237.5%

Return on equity — how efficiently it uses shareholder money

Analyst Target

N/A

Recommendation

NONE

Consensus view from ? analysts covering this stock

About Charlotte's Web Holdings, Inc.

Charlotte's Web Holdings, Inc. engages in the farming, manufacturing, marketing, and sale of hemp-derived cannabidiol (CBD) and other botanical-based wellness products. Its product categories include full-spectrum hemp extract oil tinctures, such as liquid products; gummies; capsules; soft-gels; CBD topical creams and lotions; broad-spectrum botanical CBD; functional mushrooms gummies; and pet products under the Charlotte's Web, CBD Clinic, and CBD Medic brand names. The company's products contain naturally occurring phytocannabinoids, including CBD, cannabichromene (CBC), cannabigerol (CBG), cannabinol (CBN), terpenes, flavonoids, and other beneficial hemp compounds. It distributes its products through health care practitioners and distributors, as well as online through its website and other third-party e-commerce sites. The company was formerly known as Stanley Brothers Holdings Inc. and changed its name to Charlotte's Web Holdings, Inc. in July 2018. Charlotte's Web Holdings, Inc. was founded in 2013 and is headquartered in Louisville, Colorado.

https://www.charlottesweb.com

Country: United States Industry: Drug Manufacturers - Specialty & Generic

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

83.6% FAIL

Debt must be below 33% of total assets

Cash Ratio

11.1% PASS

Interest-bearing cash below 33% of assets

Receivables

0.0% PASS

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Valuation

Fair Value Est.

$0.15

What our model estimates this business is worth per share

Margin of Safety

-188.0%

Trading above fair value — no margin of safety

Rating

AVOID

Overall assessment combining ethics, valuation, and quality

Percentile

4.3th

Ranks in the top 96% of our 13,571 screened universe

Ethical Score

10.0

Valuation Score

30.5

Quality Score

25.0

Combined

24.4

Trading at $0, 220% above fair value of $0. Fails ethical screen (Debt ratio). Ranks better than 6% of screened stocks.

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.984

Good returns relative to risk taken

Kelly Fraction

0.0132

Marginal edge — very small allocation suggested

Calmar Ratio

0.969

Acceptable balance between returns and drawdown risk

Annual Return

67.2%

Historical annualised return based on price data

Max Drawdown

-69.4%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$0.97

55% below the year high

52W Low

$0.08

476% above the year low

Avg Volume

697,908

Average daily shares traded — higher means easier to buy and sell

Short Ratio

N/A

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

0.0%

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.19

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.00

Conservative use of debt — low financial risk

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

N/A

Profit from core operations before interest and tax

Free Cash Flow

N/A

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

N/A

Loss-making — spending exceeds revenue after all costs

Recent Insider Activity

SEC Form 4 filings — what company insiders are buying and selling

Date	Insider	Title	Shares	Value
2026-04-06	Garrison (Mindy Beth)	Senior Officer of Issuer	—	—
2026-04-01	Kunkel (Raymond J)	Senior Officer of Issuer	24,451	—
2026-04-01	Kunkel (Raymond J)	Senior Officer of Issuer	38,900	—
2026-04-01	Lind (Erika Jean)	Senior Officer of Issuer	17,563	—
2026-04-01	Lind (Erika Jean)	Senior Officer of Issuer	32,258	—
2026-04-01	Stanley (Jared)	Director of Issuer	24,519	—
2026-03-31	Morachnick (William J.)	Senior Officer of Issuer	283,687	—
2025-12-31	Morachnick (William J.)	Senior Officer of Issuer	375,000	—
2025-12-31	Morachnick (William J.)	Senior Officer of Issuer	111,188	$40,805
2025-11-01	Walker (Margaret Borgia)	Director of Issuer	—	—

Source: SEC Form 4 filings via public data. View all insider activity at

Insider Intelligence

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-13

Before you go